Document 0084
 DOCN  M9440084
 TI    Tamoxifen helps postirradiation recovery of lymphocyte subpopulations
       (Meeting abstract).
 DT    9404
 AU    Lukac J; Kordic D; Kusic Z; Nuclear Medicine and Oncology Dept.,
       University Hosp. 'Sestre; milosrdnice,' Zagreb, Croatia
 SO    CCPC-93: Second International Cancer Chemo Prevention Conference. April
       28-30, 1993, Berlin, Germany, p. 102, 1993.. Unique Identifier :
       AIDSLINE ICDB/94696782
 AB    Besides its antiestrogenic activity, tamoxifen (TMX) seems to exert
       immunomodulatory effects, suppressing lymphocyte responsiveness to
       mitogens, potentiating natural killer (NK) activity and increasing the
       number of circulating NK cells as well. We have compared absolute
       numbers of CD4+ and CD8+ T lymphocytes, B lymphocytes, NK cells (CD16+)
       and monocytes in two groups of patients with ductal invasive carcinoma
       of the breast, Stage II and III, before telecobalt radiotherapy (TCT;
       postoperative, 40-55 Gy) and 4-12 mo later. One group (15 pts, 11 Stage
       II, 4 St III) received no further therapy while the other (14 pts, 10 St
       II, 4 St III) was treated with TMX, 20 mg/day. There was no difference
       between two groups in any cell count before TCT. Four to 12 mo later,
       the absolute number of CD4+ (median, [M]=0.375x10(9)/L, p=0.001), CD8+
       (0.206, p=0.001), B (0.058, p=0.004) and CD 16+ (0.089, p=0.05)
       lymphocytes was significantly decreased in patients not receiving TMX,
       compared to their pre-TCT values (M=0.778; 0.433; 0.085, respectively)
       while monocyte number showed no significant difference (M=0.244 vs
       0.196). There was no difference between pre- and post-TCT values in
       patients on TMX in any parameter tested. It seems that TMX helps
       postirradiation recovery of lymphocyte populations, which may contribute
       to patients' survival and indicate its role in chemoprevention.
 DE    B-Lymphocytes  Breast Neoplasms/*IMMUNOLOGY/RADIOTHERAPY/THERAPY
       CD4-CD8 Ratio  Carcinoma, Infiltrating
       Duct/*IMMUNOLOGY/RADIOTHERAPY/THERAPY  Female  Human  Killer Cells,
       Natural  Leukocyte Count  Monocytes  T-Lymphocytes
       Tamoxifen/*PHARMACOLOGY/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).